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Background. Options for intervention against Mycobacterium tuberculosis infection are limited by the diagnostic tools
available. The Purified Protein Derivative (PPD) skin test is thought to be non-specific, especially in tropical settings. We
compared the PPD skin test with an ELISPOT test in The Gambia. Methodology/Principal Findings. Household contacts over
six months of age of sputum smear positive TB cases and community controls were recruited. They underwent a PPD skin test
and an ELISPOT test for the T cell response to PPD and ESAT-6/CFP10 antigens. Responsiveness to M. tuberculosis exposure
was analysed according to sleeping proximity to an index case using logistic regression. 615 household contacts and 105
community controls were recruited. All three tests assessed increased significantly in positivity with increasing M. tuberculosis
exposure, the PPD skin test most dramatically (OR 15.7; 95% CI 6.6–35.3). While the PPD skin test positivity continued to trend
downwards in the community with increasing distance from a known case (61.9% to 14.3%), the PPD and ESAT-6/CFP-10
ELISPOT positivity did not. The PPD skin test was more in agreement with ESAT-6/CFP-10 ELISPOT (75%, p=0.01) than the PPD
ELISPOT (53%, p,0.0001). With increasing M. tuberculosis exposure, the proportion of ESAT-6/CFP-10 positive contacts who
were PPD skin test positive increased (p,0.0001), and the proportion of ESAT-6/CFP-10 negative contacts that were PPD skin
test negative decreased (p,0.0001); the converse did not occur. Conclusions/Significance. The PPD skin test has surprisingly
high specificity for M. tuberculosis infection from recent exposure in The Gambia. In this setting, anti-tuberculous prophylaxis
in PPD skin test positive individuals should be revisited.
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INTRODUCTION
Tuberculosis (TB) causes approximately 2 million deaths per year
globally;[1] 98% of these occur in low-income countries.[2] New
ways to tackle the epidemic in high prevalence, resource poor,
settings are urgently needed.[3] One option is to develop interven-
tions against Mycobacterium tuberculosis infection. The diagnosis of M.
tuberculosis infection in tuberculosis (TB)-endemic tropical settings
presents specific challenges. The abundance of environmental
mycobacteria makes any test using purified protein derivative
(PPD) potentially non-specific due to cross-reaction with M.
tuberculosis antigens. It is also not possible to identify a sub-
population that can be safely assumed not to be M. tuberculosis
infected.
Recently we presented a reproducible model for assessing new
diagnostic tests for M. tuberculosis infection in such a setting,[4,5]
a refinement of a model developed by Lienhardt et al.[6] Using an
ex vivo ELISPOT assay that measures the precise IFN-c T cell
response to stimulatory antigens after an overnight incubation
period, we identified that two M. tuberculosis antigens, ESAT-6 (6-
kDa early secreted antigenic target) and CFP-10 (10-kDA culture
fitrate protein) which are not found in BCG or many environ-
mental mycobacteria, together offered improved specificity over
PPD in the diagnosis of M. tuberculosis infection. However this
appeared to be at the cost of some sensitivity when assessed against
the traditional tuberculin skin test, which uses PPD. There was
also poor agreement among the two ELISPOT measures and the
PPD skin test. In the present study, we extended our exposure
model into the community to define clearly how the PPD skin test,
PPD ELISPOT test and the ESAT-6/CFP-10 ELISPOT test
relate to each other across a complete gradient of recent exposure
to a known TB case.
METHODS
Participants
Sputum smear positive TB index cases over 15 years of age and
their household contacts at least 6 months of age were recruited
consecutively and selected for ELISPOT as previously de-
scribed.[4] They were categorised according to where they slept
as a proxy of M. tuberculosis exposure: in the same bedroom as the
case, a different bedroom in the same house, or in a different
house on the same compound.[4,7]
Frequency matched community controls were recruited as
follows. The age and sex of consecutively recruited TB case
contacts were obtained from a previous case contact study in The
Gambia and allocated to a newly recruited index case households.
Index case households were asked if they were happy for
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to a previous selection process in The Gambia[6] and other
developing countries,[8] community controls were selected by
choosing a random direction from the case’s home (by spinning
a pen in the air) and visiting the second compound on the right.
The field-researchers checked that there was no history of a known
TB case within the household and then asked whether there was
anyone living the majority of the time in that compound of the
required age band (5 year age bands for those under 15 years of
age, 10 year age bands for those 15 years and older) and gender. If
there was more than one possible match, the control was selected
randomly by the toss of a coin or drawing blindly a numbered
piece of paper from a container. If there was no possible control at
that compound or refusal to participate, the process was repeated
once more.
Household contacts and community controls underwent a PPD
skin test (2 TU, PPD RT23, Statens Serum Institut, Copenhagen,
Denmark) immediately after being bled. Induration was recorded
at 48–72 hours by field staff blinded to the exposure category of the
subject. Subjects with a positive skin test (mean of the longitudinal
and transverse induration diameter $10 mm) were offered a chest
X-ray and those with symptoms underwent a clinical assessment.
Those with TB disease were referred to the National Programme
for free treatment. There is no current practice of preventive
treatment in The Gambia.
This study was approved by the joint Gambia Government/
MRC Ethics Committee.
Laboratory procedures
Sputum smears from TB index cases were prepared, stained,
cultured, identified and confirmed as previously described.[9] The
ex-vivo ELISPOT assays for IFN-c were performed as previously
described.[10] Purified Protein Derivative (M. tuberculosis, RT49,
Statens Serum Institut, Copenhagen, Denmark) was used at
10 mg/ml. The positive control was Phytohaemaglutinin (PHA;
Sigma-Aldrich, UK). All antigens were tested in duplicate wells.
ELISPOT plates were counted with an ELISPOT reader (AID-
GmbH, Strassberg, Germany). The spot forming unit (SFU)
numbers counted in each well were automatically entered into
a database. Supplementary data were entered by double data
entry. Positive test wells were pre-defined as containing at least ten
SFUs more than, and at least twice as many as, negative control
wells. PHA positive control wells were set to at least 150 SFUs
above negative control wells. Negative control wells were required
to have less than 30 SFUs. Laboratory staff were blinded as to the
exposure category of the subject tested.
Testing for HIV-1 or HIV-2 infection was by competitive
enzyme linked immunosorbent assays (Wellcome Laboratories,
Kent, UK) and Western blot (Diagnostics Pasteur, Marnes-la-
Coquette, France). HIV positive individuals were referred to
a specialist clinic that now offers free anti-retroviral treatment
according to set criteria.
Data management and analysis
All data were entered using double data entry into a relational
ACCESS database[11] and checked for errors. Random effects
logistic regression models, taking into account household cluster-
ing, were used to assess the relationship between risk factors and
test results and to provide summary p values for the comparison of
the relative ESAT-6/CFP-10 ELISPOT and skin test proportions
across the sleeping exposure gradient. Results were reported as
unadjusted and adjusted odds ratios and their 95% confidence
intervals (CI) and/or p values. Concordance between the tests was
calculated using the Kappa statistic and discordance by McNe-
mar’s test. All statistical analyses were conducted using Stata
software (version 7; Stata Corp, College Station, TX).
RESULTS
From 1 July 2002 to 9 February 2004, 209 index case households
were recruited and had ELISPOT and skin test results (Figure 1).
The final study population comprised 775 case contacts and 119
community controls. Of these, 720 were selected for, and had,
ELISPOT results and six hundred and ninety one subjects had
a PPD skin test read between 48 and 72 hours; 90 individuals had
an independent second skin test reading for quality control and
there was agreement with respect to a positive or negative result in
88 (98%). The characteristics of the community controls were
similar to the contacts with respect to sex and HIV status, but were
slightly older (mean 26.8 years vs 21.3 years; p=0.0001) and
a higher proportion had a BCG scar (59% vs 42%; p=0.0012;
Table 1).
Overall 228 (33.0%) of 691 contacts tested were PPD skin test
positive, 226 (31.4%) and 489 (67.9%) of 720 tested were
ELISPPOT positive for ESAT-6/CFP-10 and PPD respectively.
The percentage of volunteers positive increased significantly from
the community to the bedroom of a known TB index case for all
three tests, most markedly for the PPD skin test (OR 15.7, 95% CI
6.6–35.3; Table 2) and none of the tests was confounded by the
presence of a BCG scar when introduced into the logistic
regression model. Figure 2 shows the percentage of individuals
positive for each test across the exposure gradient for all those with
both ELISPOT and skin test results. Even with a conservative 10
spot cut-off used in this study, PPD ELISPOT positivity was over
60% in all exposure categories. Using an alternative 5-spot cut-off,
PPD ELISPOT positivity ranged from 81% to 90%. In contrast
PPD skin test positivity was 62% in the highest exposure category
and trended downwards to reach only 14% in the community.
This trend occurred irrespective of whether a 5, 10 or 15 mm PPD
skin test cut-off was considered. The ESAT-6/CFP-10 ELISPOT
(Figure 2B) responded to the exposure gradient more dramatically
than the PPD ELISPOT, but less dramatically than the PPD skin
test: the proportion positive by skin test was higher in the highest
exposure category and lower in the community. This finding held
true when considered separately in 3 age groups: under 10 years
old, those aged 10–30 and those over 30 years old (data not
shown).
Figure 3 shows the frequencies of a positive result for each test in
relation to each other by the use of scaled rectangle diagrams, with
areas of overlap proportional to frequency.[12] The overall
agreement was 53% between PPD ELISPOT and PPD skin
(concordance, K=0.16; discordance, p,0.0001), 58% between
PPD ELISPOT and ESAT-6/CFP-10 ELISPOT (concordance,
K=0.26; discordance, p,0.0001), but 75% between ESAT-6/
CFP-10 ELISPOT and PPD skin (concordance, K=0.43;
discordance, p=0 01). Noting the relative concordance between
the PPD skin test and the ESAT-6/CF-10 ELISPOT, we assessed
these two tests against each other in relation to the gradient of
exposure by sleeping proximity to a case (Figure 4). It can be
assumed that if test 1 is better than test 2, then the proportion of
test 2 positive individuals who are test 1 positive should increase
with increasing prevalence of true infection. Similarly, the
proportion of test 2 negative individuals that are test 2 negative
would be expected to decrease with increasing prevalence of true
infection. Indeed, the proportion of ESAT-6/CFP-10 positive
individuals that were PPD skin test positive increased significantly
with increasing exposure to an index case (Figure 4A, p,0.0001)
and the proportion of ESAT-6/CFP-10 negative individuals that
PPD Skin Test Versus ELISPOT
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contrast, the proportion of PPD skin test positive individuals that
were ESAT-6/CFP-10 positive did not increase significantly with
increasing exposure (Figure 4C, p=0.10) and the proportion of
PPD skin test negative individuals that were ESAT-6/CFP-10
negative actually increased slightly with increasing exposure
(Figure 4D, p=0.31).
DISCUSSION
This study has taken advantage of a reproducible gradient of
exposure to M. tuberculosis in a TB-endemic tropical setting and
extended it into the community. The comparison of PPD skin test
versus PPD ELISPOT revealed what one would expect when
comparing a specific test with a non-specific one across different
sub-populations with varying prevalence of true infection. Indeed
the PPD skin test was more in agreement with the ELISPOT assay
employing more specific M. tuberculosis antigens. When the PPD
skin test and the ESAT-6/CFP-10 ELISPOT were compared with
each other across the exposure gradient, the PPD skin test related
to the gradient more accurately. These results provide important
insights into the different properties of the skin test and T cell
response to mycobacterial antigens.
The finding of high specificity of the PPD skin test in settings
such as The Gambia is supported by a recent review by Farhat et
Figure 1. Study profile.
doi:10.1371/journal.pone.0000068.g001
Table 1. Characteristics of 720 TB case contacts and community controls by sleeping exposure category
..................................................................................................................................................
Characteristic Same room Different room Different house Community All
(n=135) (n=282) (n=198) (n=105) (n=720)
Age (years)
Mean (median: range) 19.4 (20:1–60) 20.3 (16:1–100) 20.9 (18:1–66) 26.8 (25:1–65) 21.3 (19:0–100)
% (n) Male 53 (71) 40 (112) 49 (98) 42 (44) 45 (325)
BCG scar %(n)
a 45 (61) 46 (129) 36 (70) 59 (61) 45 (321)
HIV positive %(n/total)
b 3.7 (5/134) 2.5 (7/280) 2.0 (4/197) 1.9 (2/103) 2.2 (16/714)
a95 volunteers had uncertain BCG scar status
b6 volunteers did not have an HIV test result
doi:10.1371/journal.pone.0000068.t001
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PPD has been reported elsewhere in Africa.[14] It has also been
shown to vary by latitude.[15] In addition, rapid reversion of
a positive PPD skin test result after BCG vaccination occurs in
tropical settings while it is more likely to be persistent in more
temperate locations and when given at an older age.[16,17] In
relation to this, the PPD skin test in The Gambia and many other
tropical settings is not affected by prior BCG vaccination, even in
young children.[4,7] These observations and the findings of the
present study may have a unifying explanation. Hoft et al[18] have
shown that regular mucosal exposure to BCG leads to suppression
of skin test responses but a significant increase in mycobacteria-
specific IFN-c responses in peripheral blood. Therefore, frequent
oral ingestion of non-pathogenic environmental mycobacteria in
TB-endemic tropical settings could result in unexpected loss of
PPD skin test reactivity over time, poor agreement between skin
test and peripheral blood responses to mycobacterial antigens and
surprisingly high PPD skin test specificity. Compartmentalisation
of the antigen-specific immune response has been well-described in
other situations and is likely to be mediated through lymphocyte
homing in response to adhesion molecules and chemokines.[19]
There is also evidence from large trials of BCG vaccine[20] that
an initial positive PPD skin test response is much more specific for
M. tuberculosis infection than one that occurs only as a result of a 2-
step procedure. Those positive by initial PPD skin test or through
a 2-step procedure, were sometimes followed in parallel with those
who were PPD skin test negative that were entered into the trials.
The MRC tuberculosis vaccines clinical trials committee presented
such a follow-up of 56,000 adolescents in 1956.[21] The incidence
rate of definite TB disease in those initially skin test positive was
175/100,000 per year compared to 74/100,000 per year in those
only positive in a two-step test. Similarly, in 1969, Comstock and
Webster reported a 20 year follow-up of school children in
Georgia, where 29/1492 (2%) of those initially positive became
definite TB cases versus 7/3768 (0.2%) of those positive through
a two-step procedure.[22]
Studies of T cell assays that employ more ESAT-6 and CFP-10
have compared them to the PPD skin test.[23,24] However, it has
been unclear what proportion of the differences, or similarities,
seen are due to the antigens versus the different immune responses
being evaluated. While the use of ESAT-6 and CFP-10 improves
specificity within the ELISPOT assay, this is at the cost of some
sensitivity in The Gambia when compared to the PPD skin test,[4]
even when a 5-spot cut-off is used (Figure 2B). We have also found
that the ELISPOT response to ESAT-6 varies according to
infecting M. tuberculosis strain.[25] Furthermore, it is known that
ESAT-6 and CFP-10 are secreted by some environmental
mycobacteria commonly encountered in The Gambia,[26,27]
potentially compromising test specificity in our setting.
Do the findings of the present study provide evidence that the
PPD skin test is actually both more sensitive and specific than the
ESAT-6/CFP-10 ELISPOT for M. tuberculosis infection in The
Gambia? The answer to that question is ‘yes and no’. It certainly
appears clear that, with respect to new infection from recent
exposure, the PPD skin test is more sensitive than the ESAT-6/
CFP-10 ELISPOT and also more specific. However, with respect
to latent infection from more distant exposure, the PPD skin test
appears to be heavily down-regulated in this TB-endemic setting
as it seems likely that more than 14% of the community are
harbouring M. tuberculosis. Therefore the interpretation of a positive
or negative ESAT-6/CFP-10 ELISPOT in the community in The
Gambia is complex. Longitudinal follow-up to identify secondary
cases will be important in trying to resolve this issue.
That the PPD skin test is negative in some individuals who may
have latent M. tuberculosis infection is of particular concern in
certain subgroups, such as those who are immunosuppressed,
where there may be a niche for new generation T cell assays in
Africa.[28] It is of particular relevance in HIV positive individuals
with advanced immunodeficiency and for those planning safety
studies of new generation TB vaccines, as it is feared that highly
immunogenic vaccines may induce a ‘Koch phenomenon’ in those
with latent M. tuberculosis infection.[29] In our new generation TB
vaccine safety studies in The Gambia, we have introduced both
ELISPOT and PPD skin test entry criteria for volunteers recruited
from the general community.
Our study has several possible sources of bias. First, refusal to
participate by some case households and a number of potential
community controls was understandable as TB cases may be
Table 2. Univariable and multivariable odds ratios for the ELISPOT and PPD skin tests by logistic regression (household as a random
effect) according to sleeping proximity to a case
..................................................................................................................................................
Antigen Sleeping proximity % (n) positive OR (95% CI) Adj. OR
a (95% CI) p
b
PPD skin test (n=691) Community 14.3 (14) 1.0 1.0
Different house 20.7 (40) 1.7 (0.8–3.5) 1.8 (0.8–3.8)
Different room 35.0 (96) 4.1 (2.1–8.2) 4.6 (2.2–9.6)
Same room 61.9 (78) 14.2 (6.6–30.3) 15.7 (7.0–35.3) 0.0001
PPD ELISPOT (n=720) Community 64.8 (68) 1.0 1.0
Different house 69.7 (138) 1.1 (0.6–2.0) 1.3 (0.7–2.4)
Different room 62.3 (177) 1.0 (0.6–1.7) 1.2 (0.7–2.0)
Same room 78.5 (106) 2.1 (1.1–4.0) 2.4 (1.2–4.8) 0.02
E/C
c ELISPOT (n=720) Community 27.6 (29) 1.0 1.0
Different house 27.8 (55) 1.1 (0.6–2.0) 1.0 (0.5–1.9)
Different room 29.8 (84) 1.2 (0.7–2.1) 1.1 (0.6–2.0)
Same room 43.0 (58) 2.3 (1.2–4.3) 2.2 (1.1–4.3) 0.02
aAdj, adjusted; variables included: age, gender, ethnic group, BCG scar status
bp –value for differences between proximities
cEsat-6/CFP-10
doi:10.1371/journal.pone.0000068.t002
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PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e68Figure 2. Percent positive for each test by exposure category.
A. PPD ELISPOT positive and percent PPD skin test positive for those with a result for both tests (n=691). PPD ELISPOT positivity is represented
according to a predetermined 10 spot cut-off (PPD ELISPOT 10) as well as an alternative 5 spot cut-off (PPD ELISPOT 5). PPD skin test positivity is
represented according to a predetermined 10 mm induration cut-off as well as 2 alternative cutoffs: 5 mm and 15 mm.
B. ESAT-6/CFP-10 ELISPOT positivity represented according to a predetermined 10 spot cut-off (EC ELISPOT 10) as well as an alternative 5 spot cut-off
(EC ELISPOT 5).
doi:10.1371/journal.pone.0000068.g002
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PLoS ONE | www.plosone.org 5 December 2006 | Issue 1 | e68Figure 3. Scaled rectangular diagrams showing relative proportions of TB case contacts who are PPD skin test positive and/or ELISPOT test result
positive in relation to each other. The sizes of the boxes are proportional to the relative number of individuals they represent and the numbers
represent numbers of individuals.
A. PPD ELISPOT and ESAT-6/CFP-10 (EC) ELISPOT (n=720)
B. PPD ELISPOT and PPD skin test (n=691)
C. ESAT-6/CFP-10 ELISPOT and PPD skin test (n=691)
doi:10.1371/journal.pone.0000068.g003
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individuals in the community are often reluctant to be bled. We
note that the characteristics and test results of the households in
this study were similar to those of the households in our previous
study.[4] Second, the community controls were slightly older than
the household contacts. Age standardised ELISPOT and skin test
positivity were not different from the crude results however (data
not shown) and one would expect older age to only increase the
proportion of individuals who are PPD skin test positive in a TB-
endemic setting.[17] Third, a higher proportion of community
controls had a BCG scar. While there is no significant effect of the
BCG scar on the PPD skin test or ELISPOT results in The
Gambia,[4] it could only be expected to result in increased
positivity by PPD skin test in these individuals.
The highest risk group for progression to TB are those most
recently infected, their risk being greatest in the first year after
exposure.[30] The results of this study suggest that the PPD skin
test has surprisingly high specificity with respect to this group in
our setting and is otherwise likely to be under anergic pressure,
becoming positive upon exposure to true pathogen. These findings
have important public health implications. There is evidence that
preventive therapy had a larger impact in the control of the TB
epidemic in the United Kingdom than either vaccination or
chemotherapy.[31] High PPD skin test specificity in The Gambia
opens up new possibilities to revisit strategies to control the TB
epidemic that include prophylaxis against the development of
disease at a population level. In our setting, 3% of PPD skin test
positive case contacts at screening become TB cases within 1 year,
versus 1% of those who are PPD skin test negative (unpublished
data). Furthermore, up to 45% of new TB cases report household
contact with a known TB case.[32] Therefore, preventive therapy
in PPD skin test positive TB case contacts may be an appropriate
and important first step.
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Figure 4. Comparison of PPD skin test and ESAT-6/CFP-10 (EC) ELISPOT test in relation to each other, expressed as percentages across exposure
category by sleeping proximity to a TB case.
A. Proportion of ESAT-6/CFP-10 positive who are PPD skin test positive (n=215)
B. Proportion of ESAT-6/CFP-10 negative who are PPD skin test negative (n=476)
C. Proportion of PPD skin test positive who are ESAT-6/CFP-10 positive (n=228)
D. Proportion of PPD skin test negative who are ESAT-6/CFP-10 negative (n=463)
doi:10.1371/journal.pone.0000068.g004
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